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Introduction
Fibrous dysplasia is a rare disease. In 50% of the cases, it affects the long bones, with the proximal femur and tibia in approximately 20% [1] . The monostotic form is 8 to 10 times more frequent than the polyostotic form, which affects half of the body [1] . The prevalence of fibrous dysplasia is not well known, but approximately 5% to 7% of benign bone changes appear to display fibrous dysplasia lesions [2, 3] . Polyostotic fibrous dysplasia is usually due to mosaicism in the GNAS1 gene located on chromosome 20q13.2. Fibrous dysplasia typically presents a benign tumor-like lesion, and malignant degeneration is rare [3] . Pathological fractures are common in areas of fibrous dysplasia. Periostal fracture healing is not usually compromised, but osteosynthesis often fails due to the progression of the disease and the frequent reduction of biomechanical strength [4, 5] .
Bone morphogenetic proteins (BMPs) are members of the transforming growth factor superfamily and are potent promoters of bone healing. There are two commercially available BMP products, BMP-2 and BMP-7. BMP-7, also referred to as osteogenic protein-1 (OP-1) or Eptotermin alfa (Osigraft; Howmedica), has been approved by the United States Food and Drug Administration for the treatment of pseudarthrosis of the tibia [6, 7] . Clinically, it has been used successfully in the treatment of pseudarthrosis of different long bones, cartilage repair, intervertebral disc repair, lumbar fusion, and endoprosthetic procedures [7] .
Here, we present a unique case of pseudarthrosis of the proximal femur in a patient with fibrous dysplasia treated successfully with BMP-7/OP-1.
Case Report
A 47-year old patient suffering from the polyostotic form of fibrous dysplasia of the right part of the body (forearm, ribs, proximal femur, lower leg) presented in our polyclinic with persistent pain of the right upper thigh, resulting in an inability of full weight-bearing for 8 months. More than six months before being seen in our clinic, he had a proximal shaft fracture due to a motorcycle accident that was initially treated by intramedullary nailing. The fracture passed through the caudal part of the area affected by the fibrous dysplasia. Pseudarthrosis was confirmed by radiology ( Figure 1) . Revision was carried out with pseudarthrosis debridement and grafting of BMP-7/OP-1 (3.5 mg Eptotermin alfa, Osigraft, Stryker, UK) mixed with blood ( Figure 2 ). The fracture clinically and radiologically healed within 4 weeks with callus formation, enabling indolent full weight-bearing after 6 weeks (Figure 3 ).
Discussion
Pathological fractures are common in areas of fibrous dysplasia, and healing is often compromised due to progression of the disease and deformities [4, 5] . To our knowledge, this is the first description of the treatment of a pseudarthrosis in fibrous dysplasia using BMP-7. The potential of BMPs has been described in various reports [6, 7] . Our results support the idea that BMPs can be used alone for the treatment of the pseudarthrosis without altering osteosynthesis. However, its potential for further treatment of fibrous dysplasia lesions needs to be evaluated. As there is a high prevalence of resorption of autogenous cancellous bone grafts and even cortical grafts when the dysplastic lesions persist [3] , this method may also improve bone grafting. Improved integration of grafts in other benign bony lesions such as cysts may be possible, although further investigation is necessary.
In conclusion, although this is the first related case that has been reported, it supports the possibility that BMP-7 can improve bone healing in compromised cases such as pseudarthrosis due to fibrous dysplasia. 
